Jubilant Life shares fall on US FDA warning letter
REUTERS - Shares in Jubilant Life Sciences Ltd (JULS.NS) fell as much as 6.9 percent on Wednesday after U.S. health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.
The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.
Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd (REDY.NS), Ranbaxy Laboratories Ltd (RANB.NS), Sun Pharmaceutical Industries Ltd (SUN.NS) and Aurobindo Pharma (ARBN.NS) have all received regulatory warning letters on compliance over the last four years.
The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.
Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The Sensex was up 0.67 percent.
(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Missouri grand jury makes decision in fatal shooting of black teen
- Hagel, under pressure, resigns as U.S. defense secretary |
- Congress signals it could back Modi's insurance reform plan
- Jindal Steel shelves $10 bln project after coal setback
- EU lawmakers say not forging ideological war against Google
The reformist government that many Indians and free-market flag-bearers had hoped would emerge after this year's election isn't in New Delhi - at least not yet. Rajasthan, derided as a poverty-stricken laggard, has taken the lead on structural reforms that, their backers argue, could also help Asia's No.3 economy as a whole to attract business and employ a fast-growing workforce. Full Article
Hyundai Motor, Kia Motors lift 2014 global sales target on China, emerging markets Full Article